Koninklijke DSM (RDSMY) Rating Increased to Hold at Zacks Investment Research

Koninklijke DSM (NASDAQ:RDSMY) was upgraded by Zacks Investment Research from a “sell” rating to a “hold” rating in a research report issued on Wednesday.

According to Zacks, “DSM N V ADR is involved in the Chemicals Industry. Their main focus is on base materials, performance materials, materials processing, base chemicals and fine chemicals and coating resins. They are also involved in the exploration and development of oil and natural gas deposits in the North Sea, as well as the licensing of chemical technology and know-how; in addition the company produces ingredients for bakery products. DSM is a world market leader in a number of products, including caprolactam, melamine and EPDM synthetic rubber. “

Separately, HSBC Holdings plc assumed coverage on Koninklijke DSM in a research report on Friday, September 1st. They issued a “buy” rating for the company.

ILLEGAL ACTIVITY NOTICE: “Koninklijke DSM (RDSMY) Rating Increased to Hold at Zacks Investment Research” was originally published by Stock Observer and is the sole property of of Stock Observer. If you are viewing this report on another site, it was copied illegally and republished in violation of U.S. & international copyright & trademark laws. The legal version of this report can be accessed at https://www.thestockobserver.com/2017/10/13/koninklijke-dsm-rdsmy-rating-increased-to-hold-at-zacks-investment-research.html.

Koninklijke DSM Company Profile

Koninklijke DSM N.V. (Royal DSM) is a global science-based company, engaged in offering health, nutrition and materials. The Company’s segments include Nutrition, Performance Materials, Innovation Center and Corporate Activities. Its Nutrition segment includes DSM Nutritional Products and DSM Food Specialties.

Receive News & Ratings for Koninklijke DSM Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Koninklijke DSM and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply